Table 1.
Criterion | Include | Exclude |
---|---|---|
A. Population |
• All ages • All genders • Confirmed HIV positive status • All risk groups (general, priority, key) • On any line of lifelong antiretroviral treatment (i.e., first, second, or third-line) • In sub-Saharan Africa |
• Pregnant women in PMTCT programs • On ART for prevention (PEP or PrEP) |
B. Intervention | • Delivery of lifelong ART that differs from standard or traditional care in terms of population, location, frequency, provider cadre, or services provided. | Report about a solely standard or traditional model for delivering ART, prior to any differentiation based on population, location, frequency, provider cadre, or services provided |
C. Required descriptive data about model |
Reports all of • Location—is care provided in the clinic, on the clinic campus, in the community or workplace, at home? • Frequency—how often does the patient interact with the healthcare system for each type of service (drug pickup, medical consultation)? • Provider—which cadre of clinical or lay staff provides the service? For example, nurses conduct the medical visits, while “expert patients” deliver drugs to the patient’s house. • Patient type and line (stable, newly initiated, not stable; first, second, or third line) • Services provided (visit intensity)—what occurs at each visit or interaction? Does visit include concomitant care or medication delivery for co-morbidities? |
Description provided does not describe all the characteristics needed to define the model |
D. Comparator | Not required—single-arm evaluations are eligible | None |
E. Outcomes |
Reports one or more of the following outcomes: • Coverage of population in need • Uptake by patients • Clinical outcome (e.g. retention in care, viral suppression) • Cost or resource allocation • Acceptability to patients or providers • Feasibility to implement |
Insufficient detail provided to estimate at least one outcome |
F. Timing | A majority of follow up data report on the delivery of antiretroviral treatment occurring in January 2016 or later | A majority of follow-up data report on the period before January 2016 |
G. Sector | Services provided to the public sector through the government managed public health infrastructure or through partner/NGO/private programs or facilities that serve the uninsured sector | Services or programs for privately (commercially) insured patients |
H. Study design |
Reports empirical data from retrospective or prospective cohort, including: • Randomized controlled trials • Observational studies (including single-arm evaluations) • Pre/post studies with or without a comparison group |
• Systematic or other reviews • Case series or reports • Treatment guidelines • Mathematical models • Editorials • Commentaries |